The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View-Reference-Cited by-同舟云学术

The Issue of Renal Safety of Zoledronic Acid from a Nephrologist's Point of View

Published:2005-05-01 Issue:5 Volume:10 Page:306-308
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Balla József¹

Affiliation:

1. Department of Nephrology and Hemodialysis Unit, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.10-5-306

Reference23 articles.

1. Renal failure associated with intravenous diphosphonates;Bounameaux;Lancet,1983

2. Comparative tolerability of drug therapies for hypercalcaemia of malignancy;Zojer;Drug Saf,1999

3. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial;Rosen;Cancer J,2001

4. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases;Berenson;Clin Cancer Res,2001

5. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease;Berenson;Cancer,2001

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effective Use of Sirolimus and Zoledronic Acid for Multiosteotic Pseudomyogenic Hemangioendothelioma of the Bone in a Child: Case Report and Review of Literature;Journal of Pediatric Hematology/Oncology;2019-07

2. Bisphosphonate therapy in metastatic carcinoma patients with chronic renal failure: are bisphosphonates an enemy or crony?;Supportive Care in Cancer;2015-03-13

3. A Modified method for reducing renal injury in zoledronic acid treatment of hypercalcemia and adverse skeletal events;Indian Journal of Palliative Care;2013

4. Osteonecrosis;Pathobiology of Cancer Regimen-Related Toxicities;2012-12-03

5. Bisphosphonates;American Journal of Therapeutics;2012-05